ARCHIVES

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

This article is from The Cancer Letter archive.

Vol. 33 No. 45 | December 7, 2007

Download PDF Visit The Full Archive

Related Articles

The Cancer Letter takes summer publication break, back Sept. 12.

August 8, 2003

Letters to The Editors: Donald Coffey Finds Sensationalism Hurts

June 6, 1997

NCI To Ask HCFA to Launch Pilot Clinical Trials Program

March 22, 1996

Avastin doubles progression-free survival in metastatic disease.

May 27, 2005

NCI Toughens Criteria for MERIT Awards

February 23, 1996

DCE Reorganization Planned To Stem Departures, Stabilize

March 24, 1995